 CNS Pharmaceuticals Incs NASDAQ: CNSP partner WPD Pharmaceuticals received a favorable opinion of the Lower Silesian Medical Chamber Ethics Committee in Wrocław, Poland, for its planned upcoming Berubicin trial in adults with Glioblastoma Multiforme GBM under the WPD-201 Clinical Trial Protocol. CNS has received study level Central IRB Approval from the Central IRB for the CNS-201 Clinical Trial Protocol. 